Jane Street’s Centessa Pharmaceuticals CNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-40,968
| Closed | -$1.63M | – | 11725 |
|
|
2026
Q1 | $1.63M | Sell |
40,968
-439,236
| -91% | -$11.2M | ﹤0.01% | 5476 |
|
|
2025
Q4 | $12M | Buy |
480,204
+456,113
| +1,893% | +$11.6M | ﹤0.01% | 2104 |
|
|
2025
Q3 | $584K | Sell |
24,091
-70,274
| -74% | -$1.25M | ﹤0.01% | 7517 |
|
|
2025
Q2 | $1.24M | Sell |
94,365
-56,931
| -38% | -$721K | ﹤0.01% | 5218 |
|
|
2025
Q1 | $2.18M | Buy |
+151,296
| New | +$2.48M | ﹤0.01% | 4220 |
|
|
2024
Q4 | – | Sell |
-177,260
| Closed | -$2.83M | – | 9524 |
|
|
2024
Q3 | $2.83M | Buy |
+177,260
| New | +$2.17M | ﹤0.01% | 3832 |
|
|
2023
Q2 | – | Sell |
-40,238
| Closed | -$155K | – | 8767 |
|
|
2023
Q1 | $155K | Buy |
40,238
+14,253
| +55% | +$52.1K | ﹤0.01% | 7997 |
|
|
2022
Q4 | $80.6K | Sell |
25,985
-3,926
| -13% | -$14.6K | ﹤0.01% | 8208 |
|
|
2022
Q3 | $120K | Sell |
29,911
-9,424
| -24% | -$43.1K | ﹤0.01% | 8548 |
|
|
2022
Q2 | $192K | Buy |
+39,335
| New | +$252K | ﹤0.01% | 8230 |
|
Jane Street's CNTA Position: Q2 2026 in Review
Jane Street sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 40,968 shares — an estimated $1.63M sold.
Jane Street first reported a position in CNTA in Q2 2022 and held it in 10 quarters. The position peaked at $12M in Q4 2025. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.
- Jane Street reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Jane Street sold 40,968 Centessa Pharmaceuticals shares in Q2 2026, an estimated $1.63M.
- Jane Street first reported a position in Centessa Pharmaceuticals in Q2 2022 and held it in 10 quarters.
- Jane Street's Centessa Pharmaceuticals position peaked at $12M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.
Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.